HA-Ahx-Ahx-Ub-PA
a potent and specific inhibitor of deubiquitylating enzymes (DUBs) containing the propargylamide (PA) warhead
Additional information
| Weight | 0.05 kg |
|---|---|
| aliquot size | |
| Applications | Crystallization, Pull down, Purification, Western Blot, Phenotypic protein profiling |
| target | |
| source | |
| shipping | |
| purity | |
| molecular weight | |
| storage | upon arrival, powder at −20°C; solution at −80°C. Please avoid multiple freeze/thaw cycles. |
| sample preparation | For detailed sample preparation see product sheet. |
| regulatory statement |
€250.00
- Description
- Additional information
- references
Description
UbiQ-078 (HA-Ahx-Ahx-Ub-PA) is a potent and specific inhibitor of deubiquitylating enzymes (DUBs) containing the propargylamide (PA) as a newly discovered DUB activity warhead.
It can be used for activity profiling experiments and determining DUB inhibitor specificity, using two unique capabilities of the PA warhead:
1. it forms a covalent linkage with (the active site Cys residue of) a DUB that can be cleaved by acid treatment (5% aq. TFA), allowing for proteomic analyses.
2. it targets all three major DUB families: UCH, USP and OTU.
UbiQ-078 is N-terminally tagged with the HA peptide sequence (YPYDVPDYA) derived from the influenza hemagglutinin protein and allows for the sensitive identification or purification of DUBs by anti-HA antibodies and/or anti-HA-agarose.
The HA tag is separated from the Ubiquitin N-terminus by two aminohexanoic acid (Ahx) linkers for efficient recognition of the tag.
Additional information
| Weight | 0.05 kg |
|---|---|
| aliquot size | |
| Applications | Crystallization, Pull down, Purification, Western Blot, Phenotypic protein profiling |
| target | |
| source | |
| shipping | |
| purity | |
| molecular weight | |
| storage | upon arrival, powder at −20°C; solution at −80°C. Please avoid multiple freeze/thaw cycles. |
| sample preparation | For detailed sample preparation see product sheet. |
| regulatory statement |
Ekkebus, R., et al. On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. J. Am. Chem. Soc. 135, 2867-2870 (2013).
http://www.ncbi.nlm.nih.gov/pubmed/23387960
Sommer, S., et al. Covalent inhibition of SUMO and ubiquitin-specific cysteine proteases by an in situ thiol-alkyne addition. Bioorg. Med. Chem. 21, 2511-2517 (2013).
http://www.ncbi.nlm.nih.gov/pubmed/23535560